← All trials
NCT03359538
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2017
- Primary completion
- Apr 19, 2019
- Completion date
- Sep 19, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 63
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Modena and Reggio EmiliaLead sponsor
- University of TurinCollaborator
- University of Eastern PiedmontCollaborator
- University of GenoaCollaborator
- University of PaviaCollaborator
- University of Modena and Reggio EmiliaCollaborator
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaCollaborator
- University of PadovaCollaborator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoCollaborator
- University of Modena and Reggio EmiliaReponsible party - principal investigator
- University of Modena and Reggio EmiliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.